A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Aim To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus determine the dose range for future clinical studies. Methods This was a two‐part randomized, placebo controlled study in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2017-11, Vol.83 (11), p.2367-2376
Hauptverfasser:	Smith, Patrick F., Krishnarajah, Janakan, Nunn, Philip A., Hill, Ron J., Karr, Dane, Tam, D., Masjedizadeh, Mohammad, Funk, Jens O., Gourlay, Steve G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Agammaglobulinaemia Tyrosine Kinase autoimmune diseases Autoimmune Diseases - drug therapy Bruton's tyrosine kinase Clinical Trials Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Half-Life Healthy Volunteers Humans Inflammation - drug therapy Leukocytes, Mononuclear - metabolism Male Placebos PRN1008 Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!